Search

Your search keyword '"Balgkouranidou, Ioanna"' showing total 4 results
Start Over Author "Balgkouranidou, Ioanna" Journal clinical chemistry and laboratory medicine
4 results on '"Balgkouranidou, Ioanna"'

3. Association between SOX17, Wif-1 and RASSF1A promoter methylation status and response to chemotherapy in patients with metastatic gastric cancer.

Author

Karamitrousis E, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, Trypsianis G, Karayiannakis A, Bolanaki H, Chatzaki E, Kolios G, Lianidou E, Lambropoulou M, and Kakolyris S

Subjects
Adaptor Proteins, Signal Transducing metabolism, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Capecitabine pharmacology, Capecitabine therapeutic use, Docetaxel pharmacology, Docetaxel therapeutic use, Gene Expression Regulation drug effects, Humans, Oxaliplatin pharmacology, Oxaliplatin therapeutic use, Promoter Regions, Genetic drug effects, SOXF Transcription Factors metabolism, Tumor Suppressor Proteins metabolism, Adaptor Proteins, Signal Transducing genetics, DNA Methylation drug effects, SOXF Transcription Factors genetics, Stomach Neoplasms drug therapy, Tumor Suppressor Proteins genetics
Published
2020
Full Text
View/download PDF

4. SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.

Author

Balgkouranidou I, Chimonidou M, Milaki G, Tsaroucha E, Kakolyris S, Georgoulias V, and Lianidou E

Subjects
Aged, Carcinoma, Non-Small-Cell Lung blood, Female, Humans, Lung Neoplasms blood, Male, Carcinoma, Non-Small-Cell Lung genetics, DNA Methylation, DNA, Neoplasm blood, DNA, Neoplasm genetics, Lung Neoplasms genetics, Promoter Regions, Genetic genetics, SOXF Transcription Factors genetics
Abstract

Background: SOX17 belongs to the high-mobility group-box transcription factor superfamily and down-regulates the Wnt pathway. The aim of our study was to evaluate the prognostic significance of SOX17 promoter methylation in circulating tumor DNA (ctDNA) in plasma of non-small cell lung cancer (NSCLC) patients., Methods: We examined the methylation status of SOX17 promoter in 57 operable NSCLC primary tumors and paired adjacent non-cancerous tissues and in ctDNA isolated from 48 corresponding plasma samples as well as in plasma from 74 patients with advanced NSCLC and 49 healthy individuals. SOX17 promoter methylation was examined by Methylation Specific PCR (MSP)., Results: In operable NSCLC, SOX17 promoter was fully methylated in primary tumors (57/57, 100%), and in corresponding ctDNA (27/48, 56.2%) while it was detected in only 1/49 (2.0%) healthy individuals. In advanced NSCLC, SOX17 promoter was methylated in ctDNA in 27/74 (36.4%) patients and OS was significantly different in favor of patients with non-methylated SOX17 promoter (p=0.012). Multivariate analysis revealed that SOX17 promoter methylation in ctDNA was an independent prognostic factor associated with OS in patients with advanced but not operable NSCLC., Conclusions: Our results show that SOX17 promoter is highly methylated in primary tumors and in corresponding plasma samples both in operable and advanced NSCLC. In the advanced setting, SOX17 promoter methylation in plasma ctDNA has a statistical significant influence on NSCLC patient's survival time. Detection of SOX17 promoter methylation in plasma provides prognostic information and merits to be further evaluated as a circulating tumor biomarker in patients with operable and advanced NSCLC.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results